New drug could treat Alzheimer's, multiple sclerosis and brain injury

A new class of drug developed at Northwestern University Feinberg School of Medicine shows early promise of being a one-size-fits-all therapy for Alzheimer's disease, Parkinson's disease, multiple sclerosis and traumatic brain injury by reducing inflammation in the brain.

Northwestern has recently been issued patents to cover this new drug class and has licensed the commercial development to a that has recently completed the first human Phase 1 clinical trial for the drug.

The drugs in this class target a particular type of , which is a common denominator in these neurological diseases and in and stroke. This inflammation, also called neuroinflammation, is increasingly believed to play a major role in the progressive damage characteristic of these and brain injuries.

By addressing brain inflammation, the new class of drugs -- represented by MW151 and MW189 -- offers an entirely different to Alzheimer's than current ones being tested to prevent the development of beta in the brain. The plaques are an indicator of the disease but not a proven cause.

A new preclinical study published today in the Journal of Neuroscience, reports that when one of the new Northwestern drugs is given to a mouse genetically engineered to develop Alzheimer's, it prevents the development of the full-blown disease. The study, from Northwestern's Feinberg School and the University of Kentucky, identifies the optimal therapeutic time window for administering the drug, which is taken orally and easily crosses the blood-brain barrier.

"This could become part of a collection of drugs you could use to prevent the development of Alzheimer's," said D. Martin Watterson, a professor of and at the Feinberg School, whose lab developed the drug. He is a coauthor of the study.

In previous animal studies, the same drug reduced the neurological damage caused by closed-head traumatic and inhibited the development of a multiple sclerosis-like disease. In these diseases as well as in Alzheimer's, the studies show the therapy is critical.

MW151 and MW189 work by preventing the damaging overproduction of brain proteins called proinflammatory cytokines. Scientists now believe overproduction of these proteins contributes to the development of many degenerative as well as to the caused by traumatic brain injury and stroke.

When too many of the cytokines are produced, the synapses of the brain begin to misfire. Eventually the entire organization of the brain falls into disarray, like a computer failing. The neurons lose their connections with each other and can eventually die. The resulting damage in the cortex and hippocampus can compromise memory and decision-making.

"In Alzheimer's disease, many people now view the progression from mild cognitive impairment to full-blown Alzheimer's as an indication of malfunctioning synapses, the pathways that allow neurons to talk to each other," said Watterson, the John G. Searle Professor of Molecular Biology and Biochemistry. "And high levels of proinflammatory cytokines can contribute to synaptic malfunction."

Because this harmful inflammatory mechanism also appears to be a major player in other neurodegenerative disorders in addition to Alzheimer's, the class of drugs represented by MW151 might hold bright potential as co-therapies for Parkinson's disease, frontotemporal dementia, amyotrophic lateral sclerosis, M.S. and the longer term complications of brain injury, Watterson said.

"We need more studies of therapeutic time windows in models of these other diseases so we can better plan future clinical trials," Watterson noted.

In the new study by Northwestern's Watterson and Linda Van Eldik, director of the University of Kentucky Sanders-Brown Center on Aging, a mouse model of Alzheimer's received MW151 three times a week starting at six months of age, right at the time the proinflammatory cytokines began to rise. This would be the comparable stage when a human patient would begin to experience mild cognitive impairment.

When the mice brains were later evaluated at 11 months (at a time when disease pathology is usually present), cytokine levels in the mice receiving the drug were restored to normal levels and their synapses were functioning normally. The inflammatory cytokine levels of the mice not receiving the drug, however, were still at abnormally high levels, and the mice had misfiring synapses.

"The drug protected against the damage associated with learning and memory impairment," Van Eldik noted. "Giving this drug before Alzheimer's memory changes are at a late stage may be a promising future approach to therapy."

DRUG INHIBITS MULTIPLE SCLEROSIS DEVELOPMENT

In M.S., overproduction of the proinflammatory cytokines damage the central nervous system and the brain. The proteins directly or indirectly destroy the insulation or coverings of the nerve cells that transmit signals down the spinal cord. When the insulation is stripped, messages aren't properly conducted down the spinal cord.

When mice that were induced to develop an M.S.-like disease received MW151 orally, they did not develop disease as severe.

"We inhibited the development of the disease," said William Karpus, the Marie A. Fleming Research Professor of Pathology at the Feinberg School. "Now we need to learn if the drug can prevent relapses of M.S." That study is ongoing in mice and the results will determine whether a patient trial will be planned.

The only current oral drug treatment for M.S. acts at the level of the lymph nodes, Karpus said. Because the brain is the site of the inflammation and damage, a drug that works in the brain is an ideal therapy.

DRUG PROTECTS BRAIN AFTER TRAUMATIC BRAIN INJURY

After a traumatic brain injury, the glia cells in the brain become hyperactive and release a continuous cascade of proinflammatory cytokines that -- in the long term -- can result in cognitive impairment and epilepsy. As a result of this hyperactivity, researchers believe the brain is more susceptible to serious damage following a second neurological injury.

In a study with mice, Mark Wainright, M.D., professor of pediatric neurology at Northwestern's Feinberg School and a physician at the Ann & Robert H. Lurie Children's Hospital of Chicago, showed that when MW151 is given during an early therapeutic window three to six hours after the injury, it blocks glial activation and prevents the flood of proinflammatory cytokines after a traumatic brain injury.

"If you took a drug like this early on after traumatic brain injury or a even a stroke, you could possibly prevent the long-term complications of that injury including the risk of seizures, cognitive impairment and, perhaps, mental health issues," Wainwright said.

Stroke also causes inflammation in the brain that may also be linked to long-term complications including epilepsy and cognitive deficits. As in traumatic brain injury, this inflammatory response is part of the recovery mechanisms used by the brain, so the use of brief and focused treatments like MW151 could prevent the harmful effects of inflammation while allowing the protective effects to occur unimpeded.

In another study, Wainwright showed MW151, when given after a traumatic brain injury, prevented the increased risk of epileptic seizures.

Related Stories

Alzheimer's disease drug treats traumatic brain injury

Jul 12, 2009

The destructive cellular pathways activated in Alzheimer's disease are also triggered following traumatic brain injury, say researchers from Georgetown University Medical Center (GUMC). They say this finding suggests that ...

Anti-inflammatory drug blocks brain plaques

Jun 24, 2008

Brain destruction in Alzheimer's disease is caused by the build-up of a protein called amyloid beta in the brain, which triggers damaging inflammation and the destruction of nerve cells. Scientists had previously shown that ...

Anti-inflammatory chemical could prevent stroke damage

Dec 05, 2011

(Medical Xpress) -- Drugs that block inflammation in the brain could help patients who have a stroke or a brain haemorrhage, Manchester scientists said today (5 December) at the British Society for Immunology Congress in ...

Recommended for you

Damage to brain networks affects stroke recovery

6 hours ago

(Medical Xpress)—Initial results of an innovative study may significantly change how some patients are evaluated after a stroke, according to researchers at Washington University School of Medicine in St. ...

Dopamine leaves its mark in brain scans

6 hours ago

Researchers use functional magnetic resonance imaging (fMRI) to identify which areas of the brain are active during specific tasks. The method reveals areas of the brain, in which energy use and hence oxygen ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

wealthychef
not rated yet Jul 24, 2012
Wow! Effing amazing.
RichMurray
not rated yet Jul 25, 2012
methanol is an unexamined co-factor for brain diseases

WC Monte paradigm -- multiple sclerosis caused by methanol being made into formaldehyde inside cells of brain blood vessel walls by ADH1 enzyme, in humans only: Rich Murray 2012.07.25

Prof. Woodrow C. Monte, Food Science and Nutrition, Arizona State University, retired 2004:

textbook, and free articles, published journal paper, and 745 free online full text pdf medical research references, along with audio and video media:

WhileScienceSleeps.com

youtube.com/user/whilesciencesleeps
19 video talks

Methanol (wood alcohol) has many sources:

aspartame, E951

smoke from wood, peat, cigarettes

fruits juices vegetables, especially tomatoes, preserved wet in cans, jars, plastics, at room temperature

many dark wines and liquors (fruit brandy is worst)

fermented, smoked, spoiled foods

fresh tomatoes, black currants

jellies, jams, and marmalades not made fresh and kept refrigerated

some coffees

chewing gum

bacteria in the colon
mjesfahani
not rated yet Jul 28, 2012
Hi,
I'm mjesfahani, http://en.wikiped...osis(MS)
read it and also be in touch with me please, your information about MS is good. I'm SP MSer.
RichMurray
not rated yet Jul 28, 2012
methanol/formaldehyde paradigm for multiple sclerosis, free full 56
page chapter 9 pdf, While Science Sleeps, 146 full text references
online, Prof. Woodrow C. Monte: Rich Murray 2012.03.20
http://rmforall.b...for.html

http://www.whiles...erences/
list of 745 free full text pdf medical research references

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.